METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL.
Yiming WuMeiling JinMike Minh FernandezKevyn Lopez HartAijun LiaoXinzhou GeStacey M FernandesTinisha McDonaldZhenhua ChenDaniel RöthLucy Y GhodaGuido MarcucciMarkus KalkumRaju K PillaiAlexey V DanilovJingyi Jessica LiJianjun ChenJennifer R BrownSteven T RosenTanya SiddiqiLili WangPublished in: Blood cancer discovery (2023)
METTL3 controls widespread splicing factor abundance via translational control of m6A-modified mRNA, contributes to RNA splicing dysregulation and disease progression in CLL, and serves as a potential therapeutic target in aggressive CLL. See related commentary by Janin and Esteller.